Karyopharm Therapeutics股价上涨18%，私下筹集3000万美元

• Karyopharm Therapeutics (KPTI) announced a $30M private placement specifically with RA Capital and an additional ~$44M of gross proceeds if the accompanying warrants are exercised in full.
• In the private placement, the company agreed to sell ~1.03M shares at a price of $6.785 per share, ~3.39M pre-funded warrants at a price of $6.7849 per pre-funded warrant, and accompanying warrants to purchase ~4.42M shares with an exercise price of $10.00 per share.
• The proceeds will be used for general corporate purposes, including to support the company's ongoing and planned clinical trial activities.
• The private placement is expected to close on or about March 26, 2026.
• The stock price jumped ~18% to $7.81 on Tuesday during pre-market hours of trading.

More on Karyopharm Therapeutics

• Karyopharm Therapeutics Inc. (KPTI) Q4 2025 Earnings Call Transcript
• Karyopharm Therapeutics Inc. 2025 Q4 - Results - Earnings Call Presentation
• Karyopharm signals $130M–$150M revenue target for 2026 with pivotal myelofibrosis data readout ahead
• Karyopharm Therapeutics GAAP EPS of -$5.71 misses by $3.67, revenue of $34.08M beats by $0.92M
• Seeking Alpha’s Quant Rating on Karyopharm Therapeutics